Everolimus (Afinitor, Zortress)
Other Medications · Approved since 2009
Description
Everolimus is an oral mTOR (mechanistic target of rapamycin) inhibitor that belongs to the class of kinase inhibitors. In colorectal cancer, everolimus is used off-label for patients with metastatic disease who have failed prior targeted therapies and chemotherapy regimens. The drug has been combined with PD-1 inhibitors and evaluated as part of individualized treatment approaches for advanced colorectal cancer patients with specific molecular profiles.
Mechanism of Action
Everolimus selectively inhibits mTOR complex 1 (mTORC1), which is a key regulator of cell growth, proliferation, and survival. By blocking mTOR signaling, everolimus disrupts protein synthesis and cellular metabolism, leading to growth arrest and apoptosis in cancer cells that are dependent on this pathway for survival.
Molecular Targets
Side Effects
Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.
Clinical Trials
Quick Info
| Brand Name | Afinitor, Zortress |
| Category | Other Medications |
 Status | Off-label |
 EMA Status | EMA Approved |
 Spain Access | Hospital use off-label in CRC |
| Administration | Oral |
| Year Approved | 2009 |
| Clinical Trials | 20 |
Related Medications
Medical Disclaimer
This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.